PR97187

Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon(R) Platform

EMERYVILLE, Calif., July 26, 2022 /PRNewswire=KYODO JBN/ --

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today

announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has

implemented the use of the Berkeley Lights Beacon(R) system for antibody

discovery, as well as cell and gene therapy and cell line development research.

Logo - https://mma.prnewswire.com/media/1078159/Berkeley_Lights_Logo.jpg  

Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical

scientists have been developing significant expertise in using the Berkeley

Lights technology and workflows. Specifically, the Beacon Platform has enabled

them to expand their antibody discovery capacity beyond traditional hybridoma

techniques.

On top of the antibody discovery expertise, Otsuka will be leveraging the

Beacon technology and workflows for use in the challenging field of cell and

gene therapy. With the use of the Beacon system for research in cell and gene

therapy, they can work rapidly and efficiently towards new discoveries.

Yue Geng, Ph.D, general manager and senior vice president of the Platform

business at Berkeley Lights, said, "Otsuka Pharmaceutical and their scientists

are a great example of a team fully leveraging the Beacon Platform capabilities

in multiple scientific disciplines. They have demonstrated themselves as a

leader in the competitive pharma market through their dedication in learning

advanced technologies and systems. We value their partnership and dedication to

research using our technologies for the success of their customers."

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling

and accelerating the rapid development and commercialization of biotherapeutics

and other cell-based products for our customers. The Berkeley Lights Platform

captures deep phenotypic, functional, and genotypic information for thousands

of single cells in parallel and can also deliver the live biology customers

desire in the form of the best cells. Our platform is a fully integrated,

end-to-end solution, comprising proprietary consumables, including our

OptoSelec chips and reagent kits, advanced automation systems, and application

software. We developed the Berkeley Lights Platform to provide the most

advanced environment for rapid functional characterization of single cells at

scale, the goal of which is to establish an industry standard for our customers

throughout their cell-based product value chain.

Forward-Looking Statements

To the extent that statements contained in this press release are not

descriptions of historical facts regarding Berkeley Lights or its products,

they are forward-looking statements reflecting the current beliefs and

expectations of management. Such forward-looking statements involve substantial

known and unknown risks and uncertainties that relate to future events, and

actual results and product performance could differ significantly from those

expressed or implied by the forward-looking statements. Berkeley Lights

undertakes no obligation to update or revise any forward-looking statements.

For a further description of the risks and uncertainties relating to the

Company's growth and continual evolution see the statements in the "Risk

Factors" sections, and elsewhere, in our filings with the U.S. Securities and

Exchange Commission.  

SOURCE Berkeley Lights, Inc.

CONTACT: Media Contact: Media@berkeleylights.com; Investor Contact:

IR@berkeleylights.com